Spots Global Cancer Trial Database for A Study of SC-007 in Subjects With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SC-007 in Subjects With Advanced Cancer
Official Title: An Open Label Study of SC-007 in Subjects With Advanced Cancer
Study ID: NCT03253185
Interventions
Study Description
Brief Summary: This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
University of California, Los Angeles, Los Angeles, California, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University-School of Medicine, Saint Louis, Missouri, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Tennessee Oncology-Sarah Cannon Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
